Jose M Baselga - Cancer Science

Author Information

Josep Baselga is a prominent figure in the field of oncology, particularly known for his contributions to breast cancer research. He is affiliated with the Human Oncology and Pathogenesis Program (HOPP) and the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, NY. Additionally, he is involved in Research & Development Oncology at AstraZeneca Pharmaceuticals in Gaithersburg, MD. His work spans a diverse range of topics within cancer research, with a notable emphasis on breast cancer therapies and molecular mechanisms underlying cancer progression and treatment resistance.

Research Contributions

Josep Baselga has made significant contributions to the understanding and treatment of breast cancer. His research involves exploring the efficacy of various drug combinations and targeted therapies, such as pertuzumab and trastuzumab in HER2-positive early breast cancer and trastuzumab deruxtecan in HER2-positive metastatic breast cancer. He has also investigated the utility of serial cfDNA NGS for genomic analysis and the impact of PIK3CA mutations on PI3K inhibitor sensitivity in breast cancer. His work is instrumental in identifying resistance mechanisms and potential drug combinations to improve cancer treatment outcomes.

Aliases

Josep Baselga is also known by several aliases, including José Baselga, J Baselga, J. M. Baselga, J. Baselga, Jose M Baselga, J M Baselga, and José Baselga.

Publication and Citation Metrics

Metric	Value
Citation Count	133002
H-index	175
Paper Count	1112

Publications:

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.

DOI: 10.1038/s41416-021-01323-y

Year: 2021

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

DOI: 10.1158/1538-7445.SABCS20-PD3-06

Year: 2021

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

DOI: 10.1016/j.ejca.2021.01.053

Year: 2021

Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study

DOI: 10.1200/PO.20.00184

Year: 2021

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

DOI: 10.1158/0008-5472.CAN-21-1208

Year: 2021

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.

DOI: 10.1038/s41523-021-00351-4

Year: 2021

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

DOI: 10.1038/s41523-021-00251-7

Year: 2021

Abstract A21: Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer

DOI: 10.1158/1557-3125.PI3K-MTOR18-A21

Year: 2020

Abstract NG16: DoublePIK3CAmutations incisincrease oncogenicity and sensitivity to PI3Kα inhibitors

DOI: 10.1158/1538-7445.am2020-ng16

Year: 2020

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma.

DOI: 10.1158/2159-8290.cd-19-0116

Year: 2020

How to Use Cosmetic Bronzers Safely?

What is Octinoxate?

What are the Benefits of CAM for Cancer Patients?

What Is the Future of T Cell Engagers in Cancer Therapy?

What is Excision Repair?

What are the Guidelines for Occupational Exposure?

What Symptoms are Associated with Cancer-Related Strictures?

How is Alpelisib Administered?

Are Cancer Patients at Higher Risk for IHD?

What are Mutagens?

Partnered Content Networks

Relevant Topics